Immunovant Inc. (NASDAQ:IMVT) traded with a subtraction of -$0.29 to $19.93 on Thursday, a downside of -1.43 percent. An average of 1,170,161 shares of common stock have been traded in the last five days. There was a gain of $0.43 in the past week, and it reached a new high 36 times over the past 12 months. The last 20 days have seen an average of 1,078,920 shares traded, while the 50-day average volume stands at 1,084,782.
IMVT stock has decreased by -7.30% in the last month. The company shares reached their 1-month lowest point of $18.82 on 08/17/23. With the stock rallying to its 52-week high on 07/19/23, shares of the company touched a low of $4.26 and a high of $25.13 in 52 weeks. It has reached a new high 10 times so far this year and achieved 12.28% or $2.27 in price. In spite of this, the price is down -20.69% from the 52-week high.
Insider Transactions
IMVT stock investors should be aware that Immunovant Inc. (IMVT) stock had its last reported insider trading activity 10 days ago on Aug 14. In this transaction, the insider spent $2,207,178. Chief Executive Officer, Salzmann Peter, disposed of 101,339 shares at a price of $21.73 on Aug 07. The insider now owns more than $2,202,096 worth of shares. Prior to that, Chief Legal Officer Levine Mark S. went on to Sale 3,917 shares at $21.63 each on Jul 26. An amount of $84,725 was transacted.
Valuation Metrics
Immunovant Inc. (IMVTstock’s beta is 0.99. Other valuation ratios to consider include the price-to-book (PB) ratio at 8.67.
Financial Health
The quick ratio of Immunovant Inc. for the three months ended June 30 was 6.80, and the current ratio was 6.80, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 30.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Immunovant Inc.’s return on assets was -59.60%.
Earnings Surprise
In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$73.94 million in the quarter, while revenues of -$59.43 million were grew 45.4%. The analyst consensus anticipated Immunovant Inc.’s latest quarter earnings to come in at -$0.45 per share, but it turned out to be -$0.57, a -26.70% surprise. For the quarter, EBITDA amounted to -$78.42 million. Shareholders own equity worth $130.67 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Immunovant Inc. (IMVT) price momentum. RSI 9-day as of the close on 23 August was 38.36%, suggesting the stock is Neutral, with historical volatility in this time frame at 46.18%.
As of today, IMVT’s price is $20.37 +2.19% or $0.43 from its 5-day moving average. IMVT is currently trading -7.87% lower than its 20-day SMA and +29.08% higher than its 100-day SMA. However, the stock’s current price level is -8.12% below the SMA50 and +66.14% above the SMA200.
The stochastic %K and %D were 37.71% and 40.02%, respectively, and the average true range (ATR) was 0.99. With the 14-day stochastic at 31.66% and the average true range at 1.02, the RSI (14) stands at 42.29%. The stock has reached -0.16 on the 9-day MACD Oscillator while the 14-day reading was at -0.65.
Analyst Ratings
BofA Securities launched coverage on Immunovant Inc. (NASDAQ: IMVT) in its analyst report released on May 01, 2023. The firm assigned the stock a Buy rating. The consensus rating for Immunovant Inc. (IMVT) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell IMVT, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 12 others rate it as a “buy”.
What is IMVT’s price target for the next 12 months?
Analysts predict a range of price targets between $28.00 and $34.00, with a median target of $31.00. Taking a look at these predictions, the average price target given by analysts for Immunovant Inc. (IMVT) stock is $31.08.
